SurVaxM Highlights: ASCO 2022

Mimivax presented encouraging findings from “SURVIVE” (Phase II a) study in patients with newly diagnosed glioblastoma (Abstract #2037)

SurVaxM mechanism of action: Immunostimulants

SurVaxM (MimiVax) is a first-in-class, patented peptide mimic immunogen that targets survivin, a cell-survival protein present in 95% of glioblastomas and many other cancers.

In ASCO 2022, the Phase IIa (Survive) results of SurVaxM immunotherapy for newly diagnosed glioblastoma were presented.  Survive is a single-arm study, which enrolled a total of 63 patients with newly diagnosed glioblastoma with a median age of 60 for those who had finished their first chemoradiation. Prior to receiving the SurVaxM priming dosages, each patient underwent craniotomy, radiation, and temozolomide treatment. Interestingly, 51% of patients throughout the research survived for at least two years after being diagnosed with glioblastoma, and 41% survived for at least three years. Patients on standard therapy do have a 16-month median chance of survival, and the patient responded well to the immunotherapy plus temozolomide based on the study. Survive study demonstrated that patients treated with SurvaxM had a significantly better survival time, with 93.7% alive a year after diagnosis, compared to the projected 65% survival based on historical research.

It is highly encouraging to see that many patients saw their tumors respond to the combination of SurVaxM and temozolomide,” For such a rare but also deadly cancer, giving those with glioblastoma greater survival is always a step in the right direction. We’re excited to see this promising immunotherapy moving forward to larger studies and studies investigating other potential applications or disease settings.”   –Expert Opinion.


Looking at the promising outcomes of SurvaxM ASCO 2022 from Survive trial, we expect a change from mono temozolimide towards a combination regimen  in the treatment paradigm for the patient with newly diagnosed glioblastoma. Moreover, SurvaxM may offer a better quality of life and prolonged survival.

Apart from this, there are other drugs that are currently being evaluated for GBM, such as paxalisib (Kazia Therapeutics), Efflorithine+Lomustine (Orbus), regorafenib (Bayer), and many more.